Drug hobbles deadly liver cancer by stifling protein production

(University of California - San Francisco) In laboratory experiments, UC San Francisco researchers successfully beat back the growth of aggressive liver cancers using a surprising new approach. Traditionally, targeted cancer therapies aim to disable proteins borne of cancer-driving genes. Instead, the UCSF scientists prevented these proteins, including those that shield tumors from the immune system, from being built in the first place.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

This study demonstrates that ROS-responsive TEP NPs are effective drug carriers for efficient intracellular delivery of hydrophobic drug, PL.Graphical abstractROS-responsive thioether-bearing polymers (TEP) were synthesized and used as drug carriers for intracellular delivery of piperlongumine (PL) in cancer cells. The PL-loaded TEP nanoparticles exhibited ROS-triggered disassembly in cancer cells, leading to efficient cancer cell-specific apoptosis.
Source: Journal of Industrial and Engineering Chemistry - Category: Chemistry Source Type: research
Conditions:   Hepatitis B Virus Positive;   Malignant Solid Neoplasm Interventions:   Other: Best Practice;   Other: Laboratory Biomarker Analysis;   Drug: Tenofovir Alafenamide Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Thoracic surgeon Dr. Robert Cameron and the Pacific Mesothelioma Center moved closer to a major treatment advance by obtaining U.S. patent approval for their novel mesenchymal stem cell research program. The patent approval in February makes the research program more attractive to potential investors who could accelerate development and change the way malignant mesothelioma is treated. “This is a big deal in the developmental path for MSC [mesenchymal stem cell] therapy,” Patent Adviser Dr. Walid Sabbagh told The Mesothelioma Center at Asbestos.com. “The patent is a pathway to really help these cancer pat...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
(Virginia Commonwealth University) More than a decade of research on the mda-7/IL-24 gene has shown that it helps to suppress a majority of cancer types, and now scientists are focusing on how the gene drives this process by influencing microRNAs. Published this week in the journal Proceedings of the National Academy of Sciences, the findings could potentially have implications beyond cancer for a variety of cardiovascular and neurodegenerative diseases caused by the same microRNA-driven processes.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Publication date: Available online 24 March 2019Source: Journal of Molecular LiquidsAuthor(s): Achal Mukhija, Nand KishoreAbstractBiocompatibility and ease of surface modification make gold nanoclusters potential to be used in nanomedicine and revolutionizing cancer therapy. Low solubility and bioavailability of drug limits the use of conventional drug administrative methods and hence the need for drug delivery vehicles arises. Different drug delivery vehicles have been used in the past but usually, the information is limited to qualitative in nature. Here, we have reported quantitative insights into interaction of human s...
Source: Journal of Molecular Liquids - Category: Molecular Biology Source Type: research
Authors: Smith WM, Purvis IJ, Bomstad CN, Labak CM, Velpula KK, Tsung AJ, Regan JN, Venkataraman S, Vibhakar R, Asuthkar S Abstract Immune checkpoints are known to contribute to tumor progression by enhancing cancer's ability to evade the immune system and metastasize. Immunotherapies, including monoclonal antibodies, have been developed to target specific immunosuppressive molecules on the membranes of cancer cells and have proven revolutionary in the field of oncology. Recently, small molecule inhibitors (SMIs) have gained increased attention in cancer research with potential applications in immunotherapy. SMIs h...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
In this study, we fabricated the hydrogel microrobot, analyzed its characteristics (shape, size, magnetization, and drug encapsulation), verified the possibilities of targeting and disassembly of the hydrogel microrobot, and proved the retrieval of MNPs and the drug delivery from the remaining PLGA–DOX particles. Additionally, we executed the drug-releasing experiment using PLGA–DOX particles and confirmed the therapeutic effect of the hydrogel microrobot through an in vitro test using Hep3B cancer cell. We conclude that the proposed hydrogel microrobot is a new type of biocompatible microrobot with the capabil...
Source: Sensors and Actuators B: Chemical - Category: Chemistry Source Type: research
Journal Name: Drug Metabolism and Personalized Therapy Volume: 34 Issue: 1 Pages: null-null
Source: Drug Metabolism and Personalized Therapy - Category: Drugs & Pharmacology Source Type: research
CONCLUSION: Evidence from both, experimental and clinical studies demonstrates that the probability of achieving local tumor control by radiation therapy depends on the complete eradication of CSC populations. The number, properties and molecular signature of CSCs are highly predictive for clinical outcome of radiotherapy, whereas targeted therapies against CSCs combined with conventional treatment are expected to provide an improved clinical response and prevent tumor relapse. In this review, we discuss the modern methods to study CSCs in radiation biology, the role of CSCs in personalized cancer therapy as well as future...
Source: International Journal of Radiation Biology - Category: Radiology Tags: Int J Radiat Biol Source Type: research
Prognostic role of Tif1γ expression and circulating tumor cells in patients with breast cancer. Mol Med Rep. 2019 Mar 14;: Authors: Cai F, Cai L, Zhou Z, Pan X, Wang M, Chen S, Luis MAF, Cen C, Biskup E Abstract Transcription intermediary factor 1γ (Tif1γ), a ubiquitous nuclear protein, is a regulator of transforming growth factor‑β (TGF‑β)/Smad signaling. Tif1γ can function as an oncogene and as a tumor suppressor. In the present study, Tif1γ levels were measured in the plasma of patients with breast cancer in order to investigate the association of Tif1&gam...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Laboratory Medicine | Liver | Urology & Nephrology